💸 The Tape

House Speaker Joanna McClinton said the quiet part out loud at a Black Cannabis Week panel on Friday. Pennsylvania has a House that already passed legalization, a governor who has put it in four consecutive budgets, and a Senate Republican majority that won't call a vote. "What it looks like for us to have change," she said, "is we have to change who is making the laws in that chamber." Sharif Street, who has carried the Senate bill for years, was more specific: Pennsylvanians "in 39 days" could put Democrats in a position to move it.

The number to remember is three. Republicans hold the Senate 27-23. Democrats need a net gain of three seats for an outright majority, or two for a 25-25 tie that Lieutenant Governor Austin Davis would break. Only half the chamber is on the ballot in November, so the map is narrow enough to name every race that matters.

The battlegrounds

Democrats have four realistic pickups and one seat they can't afford to lose.

SD-6, Bucks County. Veteran Republican Frank Farry against Bucks County Clerk of Courts Eileen Hartnett Albillar. Farry is the only Senate Republican with an AFL-CIO endorsement, which tells you how hard he's working to hold a suburban seat trending away from him. An August poll from State Navigate had Albillar ahead 46-45. That's a coin flip.

SD-16, Lehigh Valley. Jarrett Coleman, a hard-line Shapiro critic who spent last year subpoenaing the governor's home security costs, faces Lehigh County Controller Mark Pinsley. Coleman has taken more than $400,000 from skilled-games executives, which will feature in Democratic mail. Pinsley has the AFL-CIO and Our Revolution behind him.

SD-24, Montgomery County. Tracy Pennycuick, elected in 2022, defends a district Shapiro carried by seven points despite its Republican lean. Her opponent Chris Thomas is a former teacher and construction worker; Pennycuick has been on defense over a data center bill she sponsored and then campaigned against.

SD-40, the Poconos. Rosemary Brown against Brian Wrightson in a region being demographically transformed by New York and New Jersey transplants. Shapiro won it by four in 2022.

SD-36, Lancaster County. This is the one Democrats have to hold. James Malone won a March 2025 special election by fewer than 500 votes in a district Trump carried by more than 15 points, becoming the first Democrat to represent that part of Lancaster in over 130 years. He faces State Rep. Tom Jones. Lose Malone and the math becomes four flips instead of three.

Is it possible?

Yes, and the environment helps. Midterms favor the party out of the White House, Shapiro holds a commanding lead over Stacy Garrity in every public poll, and Democrats already flipped a Butler County House seat in an August special. Spotlight PA notes at least one nonpartisan forecaster calls this Democrats' best shot at a trifecta in recent memory. Republicans have held the Senate almost continuously for 45 years; the incumbents in these districts are experienced, well-funded and know how to run ahead of the top of the ticket. The honest read is that Democrats are favored to gain seats and roughly even money to gain enough of them.

What flips with the chamber

The legislative pieces are already on the table. SB 120, Street's bipartisan bill with Republican Law & Justice Chair Dan Laughlin, allows adults to possess 30 grams of flower, sets an 8% excise tax on top of the 6% sales tax, and includes expungement. Laughlin co-sponsored it and then declined to move it out of his own committee, focusing instead on SB 49, a Cannabis Control Board bill that also gutted hemp THC products and died on the floor in June with nearly every Democrat opposed. Street has a discharge resolution signed by every Democratic senator that goes nowhere in the minority and becomes an agenda item in the majority.

The House's own bill, passed last year, routes adult-use sales through state-run stores — a model Senate Republicans mocked and the industry loathes. A Democratic Senate would almost certainly land closer to SB 120's private-license framework, because that's the version its own members wrote. Jordan Harris, who chairs House Appropriations, gave the real tell: "It's going to be about the money." The Independent Fiscal Office projects nearly half a billion dollars in annual revenue by 2028, and every dollar Pennsylvanians spend in New Jersey, Maryland, Ohio and New York dispensaries is a line item Harrisburg can see.

Garrity has pledged to veto legalization if it reached her desk. She also said she doesn't think it will. If Shapiro wins by the margin the polls show, that pledge is irrelevant.

The industry that's waiting

Pennsylvania is already the second-largest medical market in the country. Dispensaries sold $922 million in the first half of 2026, up about 5% year over year, on pace for roughly $1.8 billion annually. But the wholesale line is down — grower/processors sold $297 million to dispensaries in the first half, versus $305 million a year earlier — which is what a mature medical market with 440,000-plus patients and no new demand looks like. Growth has plateaued. Adult-use is the only thing that changes the slope.

The operators have been positioning anyway. Cresco closed its $50 million acquisition of PharmaCann Penn on September 1, adding nine dispensaries to become the state's largest medical retailer alongside its wholesale lead. Vireo entered the state in July, paying about $20 million for the PhytoNatural permit that lets it open up to six stores. TerrAscend, Jushi, Green Thumb, Verano, Curaleaf and Trulieve all sit at or near the 18-store dispensary cap, which is why Cresco's deal was structured around an existing permit holder rather than new licenses. A $1.8 billion medical market with the incumbents capped is a market where every retail permit is a scarce asset, and an adult-use conversion at 8% excise would roughly double the revenue on every one of them.

There's a federal wrinkle worth flagging. Pennsylvania's operators have been in Schedule III since April, because the DOJ's rule covers cannabis sold under a state medical license — meaning they already shed 280E. If the state legalizes adult-use before the DEA extends Schedule III to recreational cannabis, the adult-use portion of their business walks back into 280E on day one. That's an argument for the ALJ moving first, not for Harrisburg waiting, but it's the kind of detail operators will model before they cheer.

The bottom line

Five races, a governor with coattails, and a bill that already has a Republican co-sponsor. Pennsylvania legalization has never been closer to a floor vote, and the industry's biggest names have spent the last twelve months buying every permit they could find. November 3 decides whether that was patience or prescience.

📈 Dog Walkers

Clean Up On Aisle 420

Colorado regulators issued a statewide recall Friday for Craft-brand vape cartridges and disposables after the products were found to have been made with an ingredient containing methylene chloride, an industrial solvent used in paint strippers, adhesives and metal cleaning. The Department of Revenue and the Department of Public Health and Environment want consumers to destroy the products or return them to the point of sale.

The scale is what makes this one notable. The affected batches — with names like "Maui Wowie," "Mango Kush" and "Diesel Dawg" — were sold at 405 dispensaries between March 27 and September 25, six months of distribution across most of the state's retail footprint. Craft is produced by Staycon LLC, a Greenwood Village company that's been operating since 2014, so this isn't a fly-by-night processor. No adverse health reports had been filed as of Friday, but the state is asking anyone who feels ill after using the products to seek care and report it.

Methylene chloride is not something that belongs anywhere near an inhalable product. The EPA's own fact sheet ties short-term exposure to central nervous system effects and chronic exposure to liver and lung cancer, which is why the agency has been restricting its industrial uses for years.

The bigger story is where it came from. The state's language — "an ingredient that contained" the solvent — points to a contaminated input rather than Staycon's own extraction process, which puts the spotlight on the terpene and diluent supply chain that feeds vape manufacturers nationwide. That's a market with thin testing requirements and, until now, little regulatory attention. Vape ingredients don't have to be cannabis to end up in a cannabis product, and most state panels don't screen for solvents that aren't on the standard residual list.

Coming two weeks after Ohio closed a dispensary over vape-related health complaints, this is the second inhalable product scare in a month. Expect regulators in other states to start asking processors where their terpenes come from.

📺 Trade To Black

Trulieve, Curaleaf Land Major Index Wins | TTB Weekly Recap

• Follow the money in Texas: Ken Paxton has taken $509,806 from the alcohol industry since 2014 while defending hemp THC restrictions and suing to overturn local decriminalization — and new CDC data shows teen use at an all-time low as states legalize.

• Index doors are opening: Trulieve joined two major S&P indices and Curaleaf was added to the FTSE Canada All Cap, unlocking passive and benchmark-driven capital that couldn't touch U.S. cannabis before.

• Green Thumb keeps buying itself: Another $50 million authorization brings cumulative repurchases to 29.5 million shares for $203.4 million since 2023, including $80 million this year.

• Cresco preps for the NYSE: Shareholders vote October 30 on redomiciling to Delaware for a senior U.S. listing — while the sector still waits on ALJ Derek Julius.